VXRT logo

Vaxart (VXRT) Company Overview

Profile

Full Name:

Vaxart, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

December 11, 1981

Indexes:

Not included

Description:

Vaxart (VXRT) is a biotechnology company focused on developing oral vaccines using its unique tablet technology. The company aims to create effective vaccines for various diseases, including COVID-19 and norovirus, to improve public health and provide easier vaccination options.

Key Details

Price

$0.74

Annual Revenue

$7.38 M(+6796.26% YoY)

Annual EPS

-$0.57(+32.14% YoY)

Annual ROE

-97.94%

Beta

2.05

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Nov 9, 2012
Splits

Next split:

N/A

Recent split:

Feb 14, 2018

Analyst ratings

Recent major analysts updates

Aug 15, 24 Oppenheimer
Outperform
Jan 31, 24 B. Riley Securities
Buy
Sep 7, 23 Cantor Fitzgerald
Overweight
Aug 7, 23 Cantor Fitzgerald
Overweight
Dec 19, 22 B. Riley Securities
Neutral
Sep 2, 22 Cantor Fitzgerald
Overweight
May 19, 22 B. Riley Securities
Neutral
Nov 2, 21 Cantor Fitzgerald
Overweight
Jun 30, 21 B. Riley Securities
Neutral
Jun 24, 21 Jefferies
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Dividend per share

Dividend yield

Other

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
VXRT
globenewswire.comJanuary 13, 2025

Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data

VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
VXRT
zacks.comNovember 13, 2024

VAXART, INC. (VXRT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10.

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
VXRT
seekingalpha.comNovember 13, 2024

Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call.

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VXRT
globenewswire.comAugust 30, 2024

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
VXRT
benzinga.comAugust 15, 2024

Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.

VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VXRT
zacks.comAugust 8, 2024

VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03.

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
VXRT
globenewswire.comAugust 2, 2024

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Vaxart Provides Business Update
Vaxart Provides Business Update
Vaxart Provides Business Update
VXRT
globenewswire.comJune 17, 2024

— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform.

Vaxart Announces $40 Million Underwritten Offering of Common Stock
Vaxart Announces $40 Million Underwritten Offering of Common Stock
Vaxart Announces $40 Million Underwritten Offering of Common Stock
VXRT
globenewswire.comJune 13, 2024

SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 17, 2024, subject to customary closing conditions.

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
VXRT
globenewswire.comJune 13, 2024

— 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Vaxart?
  • Does Vaxart pay dividends?
  • What sector is Vaxart in?
  • What industry is Vaxart in?
  • What country is Vaxart based in?
  • When did Vaxart go public?
  • Is Vaxart in the S&P 500?
  • Is Vaxart in the NASDAQ 100?
  • Is Vaxart in the Dow Jones?
  • When was Vaxart's last earnings report?
  • When does Vaxart report earnings?
  • Should I buy Vaxart stock now?

What is the ticker symbol for Vaxart?

The ticker symbol for Vaxart is NASDAQ:VXRT

Does Vaxart pay dividends?

No, Vaxart does not pay dividends

What sector is Vaxart in?

Vaxart is in the Healthcare sector

What industry is Vaxart in?

Vaxart is in the Biotechnology industry

What country is Vaxart based in?

Vaxart is headquartered in United States

When did Vaxart go public?

Vaxart's initial public offering (IPO) was on December 11, 1981

Is Vaxart in the S&P 500?

No, Vaxart is not included in the S&P 500 index

Is Vaxart in the NASDAQ 100?

No, Vaxart is not included in the NASDAQ 100 index

Is Vaxart in the Dow Jones?

No, Vaxart is not included in the Dow Jones index

When was Vaxart's last earnings report?

Vaxart's most recent earnings report was on Nov 13, 2024

When does Vaxart report earnings?

The next expected earnings date for Vaxart is Mar 14, 2025

Should I buy Vaxart stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions